Improving Executive Functioning After Traumatic Brain Injury (TBI): A Trial of the "Short Term Executive Plus" Program (STEP)

September 23, 2013 updated by: Icahn School of Medicine at Mount Sinai

Short-Term Executive Plus (STEP): A Randomized Controlled Trial of Short Term Intensive Cognitive Rehabilitation.

The purpose of this study is to determine the efficacy of an intensive short term cognitive rehabilitation program aimed towards improving executive functioning in individuals with traumatic brain injury (TBI).

Study Overview

Status

Completed

Detailed Description

Executive dysfunction following brain injury (BI) is commonly observed and has been well documented in the literature (Mateer, 1999; Prigatano, 1999; Levine et al., 2000; Shallice & Burgess, 1991; Cicerone & Giacino, 1992; Goldman-Rakic, 1993; Lezak, 1995, Riegal & Gauggel, 2002; McDonald, 2002; Stuss and Levine, 2003). Level of functioning such as vocational success, community reintegration, and social autonomy are associated with executive functioning abilities following BI (Mazaux et al. 1997, Sohlberg, Mateer, & Stuss, 1993; (Stuss & Levine, 2002, McDonald, 2002). Studies describing the rehabilitation of executive dysfunction have been limited to mostly single case or small group designs (Cicerone, et al., 2000). However, there have been three small randomized clinical trials that have had promising results suggesting the need for more research in this area. When considering all of the studies, it is evident that emphasis has been placed on three areas of intervention: attention remediation, emotional regulation and problem-solving. Consequently, given the pervasive disability found in individuals with BI that is secondary to executive function disorders and the promising, but limited, success of problem-solving-based interventions for executive functions, a randomized controlled trial (RCT) of the efficacy of a short-term, intensive executive function training program (Short-Term Executive Plus) is proposed. The Short-Term Executive Plus (STEP) program will combine treatments and treatment approaches that have proved to be effective in previous studies and will be compared to "wait-list" control group. This design was chosen because no appropriate control intervention exists. In other words there is no "standard" rehabilitation treatment available to these individuals that could serve as an appropriate "control" condition/treatment. As discussed earlier, cognitive remediation is typically delivered in extended full-time day treatment programs or weekly/bi-weekly individual sessions. Using more traditional extended treatments as a control condition would be inappropriate, as persons who can participate in extended, full-time are not the target of the proposed intervention. It is hypothesized that the STEP program will result in significant improvements in executive functioning (and related areas of attention, memory, community participation, and life satisfaction).

Study Type

Interventional

Enrollment (Actual)

101

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • New York
      • New York, New York, United States, 10029-6574
        • Icahn School of Medicine at Mount Sinaï

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Be 18 years old or older;
  • Having a TBI as a result of a blow to the head followed by a loss of consciousness or period of being dazed and confused or a period of post traumatic amnesia or clinical signs of altered neurological function; this information must be medically documented (e.g., emergency medical record, hospital record, neuroradiological report, or neurological exam or record of physician's visit within 24 hours of injury);
  • Being at least three months post-injury;
  • Being English-speaking (treatment sessions will be conducted in English);
  • Reporting executive dysfunction (by self or family);
  • Being willing and able to participate in and travel to the program daily for three months;
  • Being oriented to time, place and person;
  • Having a full-scale IQ of at least 75;
  • Having a score on the Galveston Orientation and Amnesia Test of 75 or more;
  • Having communication skills adequate to participate in groups;
  • Having at least a sixth-grade reading level (for testing and use of written materials);
  • Being willing to complete questionnaires and interviews about mood, thinking skills, participation and the like; AND
  • Agreeing to participate, i.e., completion of informed consent and HIPAA documents.

Exclusion Criteria:

  • Have diminished mental capacity and as a result, are unable to sign informed consent;
  • Active substance abuse;
  • Active psychosis;
  • Active suicidality;
  • Disruptive or violent behavior to self or others;
  • Current cognitive rehabilitation (this will not include current psychotherapy);
  • No impairment on the FRSBE or WCST; OR
  • Showing evidence of or a diagnosis of dementia or mild cognitive impairment.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Crossover Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Immediate start
Starts the 12 week intervention immediately after enrollment
Participation in an intensive cognitive rehabilitation program 3 days a week (3 hours a day) for 12 weeks. Each day consists of a 50 minutes of problem solving group, 50 minutes of individualized attention training, and a 50 minute emotional regulation group session with 10 minutes breaks between each module.
Experimental: Waitlist group
Starts the 12 week intervention 12 weeks after initial enrollment
Participation in an intensive cognitive rehabilitation program 3 days a week (3 hours a day) for 12 weeks. Each day consists of a 50 minutes of problem solving group, 50 minutes of individualized attention training, and a 50 minute emotional regulation group session with 10 minutes breaks between each module.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
Executive functioning
Time Frame: At the beginning of the intervention
At the beginning of the intervention
Executive functioning
Time Frame: At 12 weeks
At 12 weeks
Executive functioning
Time Frame: At 24 weeks
At 24 weeks
Executive functioning
Time Frame: At 6 months
At 6 months
Executive functioning
Time Frame: At 1 year post-intervention.
At 1 year post-intervention.

Secondary Outcome Measures

Outcome Measure
Time Frame
Attention
Time Frame: At the beginning of the intervention
At the beginning of the intervention
Attention
Time Frame: At 12 weeks
At 12 weeks
Attention
Time Frame: At 24 weeks
At 24 weeks
Attention
Time Frame: At 6 months
At 6 months
Attention
Time Frame: At 1 year post-intervention
At 1 year post-intervention
Depression and anxiety
Time Frame: At the beginning of the intervention
At the beginning of the intervention
Depression and anxiety
Time Frame: At 12 weeks
At 12 weeks
Depression and anxiety
Time Frame: At 24 weeks
At 24 weeks
Depression and anxiety
Time Frame: At 6 months
At 6 months
Depression and anxiety
Time Frame: At 1 year post-intervention
At 1 year post-intervention
Memory and learning
Time Frame: At the beginning of the intervention
At the beginning of the intervention
Memory and learning
Time Frame: At 12 weeks
At 12 weeks
Memory and learning
Time Frame: At 24 weeks
At 24 weeks
Memory and learning
Time Frame: At 6 months
At 6 months
Memory and learning
Time Frame: At 1 year post-intervention
At 1 year post-intervention
Participation, life satisfaction, and self-efficacy
Time Frame: At the beginning of the intervention
At the beginning of the intervention
Participation, life satisfaction, and self-efficacy
Time Frame: At 12 weeks
At 12 weeks
Participation, life satisfaction, and self-efficacy
Time Frame: At 24 weeks
At 24 weeks
Participation, life satisfaction, and self-efficacy
Time Frame: At 6 months
At 6 months
Participation, life satisfaction, and self-efficacy
Time Frame: At 1 year post-intervention
At 1 year post-intervention

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Wayne Gordon, Ph.D., Icahn School of Medicine at Mount Sinaï

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

January 1, 2008

Primary Completion (Actual)

July 1, 2012

Study Completion (Actual)

July 1, 2013

Study Registration Dates

First Submitted

February 20, 2008

First Submitted That Met QC Criteria

February 28, 2008

First Posted (Estimate)

February 29, 2008

Study Record Updates

Last Update Posted (Estimate)

September 24, 2013

Last Update Submitted That Met QC Criteria

September 23, 2013

Last Verified

September 1, 2013

More Information

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Traumatic Brain Injury

Clinical Trials on Immediate Start

Subscribe